Kiniksa Pharmaceuticals International, plcKNSA
| Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net income (loss) | -103 | -162 | -161 | -158 | 183 | 14 | -43 |
|---|
| Depreciation and amortization expense | - | - | - | 2 | 2 | 2 | 2 |
|---|
| Share-based compensation expense | 6 | 15 | 21 | 25 | 25 | 27 | 31 |
|---|
| Noncash Lease Expense | - | 1 | 1 | 3 | 3 | 3 | 3 |
|---|
| Amortization (accretion) of discounts on short-term investments | 1 | 4 | -0 | -1 | 0 | 1 | -0 |
|---|
| Gain on disposal of property and equipment | - | - | - | - | - | - | 0 |
|---|
| Loss on disposal of property and equipment | -0 | -0 | - | -0 | -0 | -0 | -0 |
|---|
| Deferred income taxes | -1 | -3 | 4 | 0 | -185 | -34 | 8 |
|---|
| Prepaid expenses and other current assets | 5 | 1 | 1 | -3 | 4 | 7 | 3 |
|---|
| Accounts receivable, net | - | - | - | 4 | 9 | 9 | 20 |
|---|
| Inventory | - | - | - | 4 | 18 | 10 | -5 |
|---|
| Contract asset | - | - | - | - | 8 | -8 | - |
|---|
| Other long-term assets | - | - | 6 | 3 | -3 | -5 | 10 |
|---|
| Accounts payable | 9 | -5 | -5 | 1 | 6 | 0 | -6 |
|---|
| Increase (Decrease) in Accrued Liabilities | 9 | 5 | 9 | 10 | -4 | 17 | 44 |
|---|
| Operating lease liabilities | - | -1 | -2 | -3 | -3 | -3 | -4 |
|---|
| Deferred revenue | - | - | - | - | 12 | 0 | 20 |
|---|
| Other long-term liabilities | - | 0 | 0 | -1 | 2 | 0 | -0 |
|---|
| Net cash provided by operating activities | -81 | -158 | -137 | -126 | 6 | 13 | 26 |
|---|
| Proceeds from sale of property and equipment | - | - | - | - | 0 | - | 0 |
|---|
| Purchases of property and equipment | 5 | 3 | 0 | 0 | 0 | 0 | 0 |
|---|
| Purchases of short-term investments | 402 | 489 | 430 | 157 | 136 | 205 | 202 |
|---|
| Proceeds from the maturities of short-term investments | 168 | 541 | 407 | 306 | 128 | 176 | 240 |
|---|
| Net cash provided by (used in) investing activities | -239 | 49 | -23 | 129 | -8 | -30 | 38 |
|---|
| Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised | - | - | - | 6 | 3 | 4 | 17 |
|---|
| Payments in connection with ordinary stock tendered for employee tax obligations | - | - | - | - | 1 | 2 | 5 |
|---|
| Net cash provided by financing activities | 347 | 84 | 227 | 6 | 3 | 1 | 12 |
|---|
| Net increase (decrease) in cash and cash equivalents | 27 | -25 | 67 | 8 | 0 | -15 | 76 |
|---|
| Income Taxes Paid, Net | - | - | - | 1 | 11 | 6 | 2 |
|---|
| Change In Right Of Use Asset, New, Modified, and Terminated Leases | - | - | - | - | - | 10 | 2 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 1 | 0 | - | - | - | 0 | 0 |
|---|